Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

来自 Nature

阅读量：

作者：

Cook，David，Brown，Dearg，Alexander，Robert，March，Ruth，Morgan，Paul

展开

摘要：

Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.

展开

DOI：

10.1038/nrd4309

被引量：

383

年份：

2014